Adaptive chemo strategy aims to double pancreatic cancer surgery success
NCT ID NCT04594772
First seen Jun 04, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This phase II trial tests an adaptive chemotherapy approach for people with pancreatic cancer that can be surgically removed or is borderline removable. The goal is to see if adjusting the chemotherapy regimen based on early response can increase the number of patients who become eligible for surgery. About 32 participants will receive standard FOLFIRINOX or gemcitabine-based therapy, with the option to switch if needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Arizona
Tucson, Arizona, 85724, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFIRINOX (combination of 5-fluorouracil, irinotecan, and oxaliplatin) and gemcitabine with nab-paclitaxel
What this could lead to
If successful, this approach could help more patients with pancreatic cancer become eligible for surgery, potentially improving survival.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. Chemotherapy side effects can be severe.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.